AR106307A1 - Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos - Google Patents
Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismosInfo
- Publication number
- AR106307A1 AR106307A1 ARP160103089A ARP160103089A AR106307A1 AR 106307 A1 AR106307 A1 AR 106307A1 AR P160103089 A ARP160103089 A AR P160103089A AR P160103089 A ARP160103089 A AR P160103089A AR 106307 A1 AR106307 A1 AR 106307A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- substituted
- basic
- binding portion
- antigen binding
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 230000036571 hydration Effects 0.000 title 1
- 238000006703 hydration reaction Methods 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 11
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 125000000539 amino acid group Chemical group 0.000 abstract 5
- 230000002209 hydrophobic effect Effects 0.000 abstract 4
- 230000007935 neutral effect Effects 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238680P | 2015-10-07 | 2015-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106307A1 true AR106307A1 (es) | 2018-01-03 |
Family
ID=58488607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103089A AR106307A1 (es) | 2015-10-07 | 2016-10-07 | Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501532B2 (enExample) |
| EP (1) | EP3359193A4 (enExample) |
| JP (1) | JP2018536628A (enExample) |
| KR (1) | KR20180077181A (enExample) |
| CN (1) | CN108472362B (enExample) |
| AR (1) | AR106307A1 (enExample) |
| AU (1) | AU2016335842A1 (enExample) |
| BR (1) | BR112018006140A2 (enExample) |
| CA (1) | CA3000531A1 (enExample) |
| IL (1) | IL257956A (enExample) |
| TW (1) | TWI704159B (enExample) |
| WO (1) | WO2017062792A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ714555A (en) | 2013-09-17 | 2020-03-27 | Obi Pharma Inc | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| EP3344806A4 (en) | 2015-09-04 | 2019-03-20 | OBI Pharma, Inc. | GLYCANARRAYS AND METHOD OF USE |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| CA3021548A1 (en) | 2016-04-22 | 2017-10-26 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| AU2017302038B2 (en) | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| KR102528998B1 (ko) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | 인간 항체, 제약 조성물 및 방법 |
| US11000601B2 (en) | 2016-11-21 | 2021-05-11 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| WO2018218068A1 (en) * | 2017-05-24 | 2018-11-29 | Development Center For Biotechnology | Humanized antibodies against globo h and uses thereof in cancer treatments |
| CN111683961A (zh) * | 2018-03-13 | 2020-09-18 | 豪夫迈·罗氏有限公司 | 4-1bb激动剂与抗cd20抗体的治疗剂组合 |
| WO2019232519A1 (en) * | 2018-06-01 | 2019-12-05 | Obi Pharma, Inc. | Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| CN116589572B (zh) * | 2023-06-28 | 2023-11-10 | 湖南诺合新生物科技有限公司 | 一种抗ha标签的单克隆抗体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| WO2005010049A2 (en) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| JP4942664B2 (ja) * | 2005-02-01 | 2012-05-30 | モーフォシス アーゲー | 抗体を単離するためのライブラリおよび方法 |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| TWI392502B (zh) * | 2009-06-16 | 2013-04-11 | Academia Sinica | 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗 |
| JP5906233B2 (ja) * | 2010-04-09 | 2016-04-20 | アベオ ファーマシューティカルズ， インコーポレイテッド | 抗ＥｒｂＢ３抗体 |
| AU2012279288B2 (en) | 2011-07-01 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| WO2015015629A1 (ja) | 2013-08-02 | 2015-02-05 | 株式会社日立製作所 | 炭化珪素半導体装置および炭化珪素半導体装置の製造方法 |
| CN104693305A (zh) | 2013-12-04 | 2015-06-10 | 苏州中赢医疗科技有限公司 | 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用 |
| TW201622743A (zh) | 2014-03-19 | 2016-07-01 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 免疫原醣肽、包含該醣肽之組合物及其用途 |
| EP3129048B1 (en) | 2014-04-10 | 2020-01-15 | OBI Pharma Inc. | Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof |
-
2016
- 2016-10-07 BR BR112018006140A patent/BR112018006140A2/pt not_active IP Right Cessation
- 2016-10-07 EP EP16854440.1A patent/EP3359193A4/en not_active Withdrawn
- 2016-10-07 AU AU2016335842A patent/AU2016335842A1/en not_active Abandoned
- 2016-10-07 CN CN201680056209.7A patent/CN108472362B/zh active Active
- 2016-10-07 TW TW105132620A patent/TWI704159B/zh active
- 2016-10-07 JP JP2018516418A patent/JP2018536628A/ja active Pending
- 2016-10-07 US US15/288,562 patent/US10501532B2/en active Active
- 2016-10-07 KR KR1020187012974A patent/KR20180077181A/ko not_active Withdrawn
- 2016-10-07 AR ARP160103089A patent/AR106307A1/es unknown
- 2016-10-07 CA CA3000531A patent/CA3000531A1/en not_active Abandoned
- 2016-10-07 WO PCT/US2016/056032 patent/WO2017062792A1/en not_active Ceased
-
2018
- 2018-03-07 IL IL257956A patent/IL257956A/en unknown
-
2019
- 2019-08-21 US US16/547,009 patent/US11236154B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108472362B (zh) | 2022-03-29 |
| TW201718658A (zh) | 2017-06-01 |
| BR112018006140A2 (pt) | 2018-10-23 |
| IL257956A (en) | 2018-06-28 |
| TWI704159B (zh) | 2020-09-11 |
| EP3359193A1 (en) | 2018-08-15 |
| CN108472362A (zh) | 2018-08-31 |
| WO2017062792A1 (en) | 2017-04-13 |
| AU2016335842A1 (en) | 2018-04-12 |
| EP3359193A4 (en) | 2019-05-08 |
| KR20180077181A (ko) | 2018-07-06 |
| US10501532B2 (en) | 2019-12-10 |
| HK1256414A1 (zh) | 2019-09-20 |
| US20170101462A1 (en) | 2017-04-13 |
| JP2018536628A (ja) | 2018-12-13 |
| CA3000531A1 (en) | 2017-04-13 |
| US11236154B2 (en) | 2022-02-01 |
| US20200048334A1 (en) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106307A1 (es) | Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| BR112019003775A2 (pt) | anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| PH12016502590B1 (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof | |
| PE20191487A1 (es) | Anticuerpos anti-gitr y metodos de uso de los mismos | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |